Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sunday, July 12, 1:29 PM
| This Slide: #136 of 666 |
Slide #136. Tonix Pharmaceuticals Holding Corp. — Preferred Stock Offering
| Company: | Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) |
| Date announced: | 10/25/2022 |
| Shares Offered: | 100,000 |
| Date of Pricing: | 10/25/2022 |
| Price Per Share: | $9.50 |
| Preferred Stock Offering Details: | Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $9.50, representing an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $1.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of shareholder approval for an increase to the authorized shares of common stock of the Company from 150 million to 1 billion. The Company and the holders of the Series A and Series B preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred stock. Total gross proceeds from the offerings, before deducting discounts, placement agent's fees and other estimated offering expenses, is $15 million. |
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation.
Open the TNXP Page at Preferred Stock Channel »
|
||||||||||||
|
|
Open the TNXP Page at Preferred Stock Channel (in a new window) »
|
Browse preferred stock yield screens, safer-income pages, offerings research, valuation and liquidation-preference screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan. Preferred Yield and Income ScreensCore PreferredStockChannel pages focused on high-yield preferreds, socially responsible income ideas, and safer-income preferred research. Offerings, Structure, and Screening ToolsPages for recent preferred offerings, preferreds by index membership or industry, and insider-related screening ideas. Premium, Discount, and Relative Value ScreensPages centered on preferred stock pricing relative to liquidation preference and comparative value signals. Dividend and Cross-Network Income ResearchRelated dividend and income pages from across the network that support preferred-stock investors comparing income vehicles. Analyst and Broader Market ResearchBroader analyst and market pages that remain part of the live homepage inventory. |
|
|
